Loading...
Docoh

Cellectis (CLLS)

Utility
Methods for engineering highly active T cell for immunotherapy
26 Apr 22
The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 14
Utility
Methods for altering amino acid content in plants through frameshift mutations
26 Apr 22
Materials and methods are provided for making plants with altered levels of amino acids, particularly by making controlled frameshift mutations in genes that are highly expressed in plant leaves or plant seeds.
Nicholas Baltes, Song Luo
Filed: 16 Nov 17
Utility
Methods for engineering allogeneic and highly active t cell for immunotherapy
19 Apr 22
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 14
Utility
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
15 Mar 22
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 11 Mar 21
Utility
Inhibitory Chimeric Antigen Receptors
3 Feb 22
ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 26 Jul 21
Utility
Method for the Generation of Compact Tale-nucleases and Uses Thereof
13 Jan 22
The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA.
Philippe Duchateau, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat, Marine Beurdeley
Filed: 29 Sep 21
Utility
Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domains
11 Jan 22
The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids.
Philippe Duchateau, Julien Valton
Filed: 9 Apr 19
Utility
Method for the generation of compact tale-nucleases and uses thereof
14 Dec 21
The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA.
Philippe Duchateau, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat, Marine Beurdeley
Filed: 14 Mar 16
Utility
Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
30 Nov 21
The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism.
Philippe Duchateau, Jean-Pierre Cabaniols, Julien Valton, Laurent Poirot
Filed: 11 Mar 16
Utility
Tale-protein scaffolds and uses thereof
5 Oct 21
The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids.
Philippe Duchateau, Alexandre Juillerat, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva
Filed: 2 Jan 19
Utility
Canola with High Oleic Acid
9 Sep 21
Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein.
Wenzheng ZHANG, Feng ZHANG
Filed: 9 Jul 19
Utility
Chimeric Antigen Receptors (Car)-expressing Cells and Combination Treatment for Immunotherapy of Patients with Relapse Refractory Adverse Genetic Risk Aml
2 Sep 21
The present invention relates to compositions comprising engineered allogenic immune cells endowed with Chimeric Antigen Receptors (CAR), in particular a CAR specific for CD123 and CLL1 for treating AML patients with adverse genetic risk.
Stéphane André DEPIL, Ghulam MUFTI, David SOURDIVE
Filed: 14 Jun 19
Utility
CD19 specific chimeric antigen receptor and uses thereof
3 Aug 21
The present invention relates to chimeric antigen receptors (CAR).
Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
Filed: 16 Nov 20
Utility
Inhibitory chimeric antigen receptors
27 Jul 21
The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 9 Nov 15
Utility
Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells
22 Jul 21
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 11 Mar 21
Utility
Universal ANTI-CD22 Chimeric Antigen Receptor Engineered Immune Cells
3 Jun 21
The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells.
Julianne Smith, Philippe Duchateau, Murielle Derrien
Filed: 30 Mar 18
Utility
CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy
3 Jun 21
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells.
Roman GALETTO
Filed: 17 Dec 20
Utility
Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
25 May 21
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells.
Julianne Smith, Julien Valton, Alexandre Juillerat, Philippe Duchateau, Barbra Johnson Sasu, Arvind Rajpal
Filed: 25 Jan 16
Utility
Methods for Engineering T Cells for Immunotherapy by Using Rna-guided Cas Nuclease System
20 May 21
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe DUCHATEAU, André CHOULIKA, Laurent POIROT
Filed: 20 Nov 20
Utility
CD19 specific chimeric antigen receptor and uses thereof
18 May 21
The present invention relates to chimeric antigen receptors (CAR).
Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
Filed: 16 Nov 20
Patents are sorted by USPTO publication date, most recent first